List view / Grid view
12 January 2016 | By Victoria White
An analyst at GBI Research states that the pipeline for the disease is highly active, consisting of 365 programmes across all stages of development, and a diverse range of molecular targets...
12 January 2016 | By Victoria White
Nestlé Health Science has signed an exclusive agreement outside the US and Canada for Seres Therapeutics’ Ecobiotics in clostridium difficile infections and inflammatory bowel disease...
12 January 2016 | By Victoria White
Eisai has submitted the MAA to the EMA for the use of lenvatinib in combination with everolimus to treat people with unresectable advanced or metastatic renal cell carcinoma who have received one prior vascular endothelial growth factor targeted therapy...
11 January 2016 | By Victoria White
The company will first be evaluating foralumab in two clinical indications: graft vs host disease; and ulcerative colitis...
11 January 2016 | By Victoria White
The combination of Shire and Baxalta will create the number one rare diseases platform in revenue and pipeline depth...
11 January 2016 | By Victoria White
AbbVie's investigational HCV regimen, combining ABT-493 and ABT-530, will be evaluated in patients with genotypes 1-6 chronic HCV infection...
11 January 2016 | By Victoria White
Incyte and AstraZeneca are to evaluate the efficacy and safety of Incyte's INCB39110 in combination with AstraZeneca's Tagrisso (osimertinib) as a second-line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who have been treated with a first generation EGFR tyrosine kinase inhibitor (TKI) and subsequently developed the…
11 January 2016 | By Victoria White
Cancer vaccine SCIB1 is a DNA ImmunoBody immunotherapy encoding a human IgG1 antibody, with three epitopes from gp100 and one from TRP-2 engineered into its CDR regions...
11 January 2016 | By Victoria White
Oral mucositis is a common and often debilitating complication of cancer treatment which affects 80% of patients with head and neck cancer receiving radiotherapy...
8 January 2016 | By Victoria White
ViiV Healthcare has formalised its collaboration with Janssen for the Phase III investigation and commercialisation of the injectable formulations of cabotegravir and rilpivirine...
8 January 2016 | By Victoria White
Median overall survival from the updated study results was 11.4 months in people with higher levels of PD-L1 expression, and 7.9 months in the overall study population...
8 January 2016 | By Victoria White
GlobalData states that the leading driver of this reasonably robust growth will be the anticipated launches of five biologics for the treatment of various forms of vasculitis...
7 January 2016 | By RADWAG
The X2 series embodies synergy between conventional solutions characteristic for high quality balances, and technology intended mainly for professional standards...
7 January 2016 | By Nicholas Jackson
Faron has announced that its Japanese licensing partner Maruishi has obtained positive results from the Phase II Japanese study for Traumakine conducted by Maruishi in Japan...
7 January 2016 | By Nicholas Jackson
DS Biopharma has announced positive top-line Phase IIa trial results for DS107 as an oral treatment for moderate to severe atopic dermatitis...
